skip to Main Content
Dr. Bert Vogelstein, pancreatic cancer researcher

FDA Approves Pembrolizumab for Pancreatic Cancers with Mismatch Repair Deficiency

Support from the Lustgarten Foundation was critical to the success of the clinical trial that demonstrated the efficacy of pembrolizumab to the FDA. In addition to supporting the research, the Foundation has been encouraging and covering the cost for pancreatic cancer patients to receive mismatch repair deficiency (MMR) testing in an effort to increase enrollment…

Back To Top